Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month. Evenity could have been on the ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...

Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting at the JP Morgan Healthcare Conference 2025 on 13 ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.